ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

New England Journal of Medicine

Volumn 352, Issue 12, 2005, Pages 1197-1205

  Reyes, Félix ^a   Lepage, Eric ^a   Ganem, Gérard ^b   Molina, Thierry J ^c   Brice, Pauline ^d   Coiffier, Bertrand ^e   Morel, Pierre ^f   Ferme, Christophe ^g   Bosly, Andre ^k   Lederlin, Pierre ^h   Laurent, Guy ⁱ   Tilly, Hervé ^j  

^a HENRI MONDOR HOSPITAL   (France)

^b Clinique Victor Hugo   (France)

^c HÔTEL DIEU   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f Centre Hospitalier de LENS   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h CHU NANCY BRABOIS   (France)

ⁱ CHU PURPAN   (France)

^j CENTRE HENRI BECQUEREL   (France)

^k UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAROTID ARTERY OBSTRUCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTRITIS; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; INFECTION; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; TREATMENT OUTCOME; VERTEBRA FRACTURE; XEROSTOMIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDNISONE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE; VINDESINE;

EID: 20144369743     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa042040     Document Type: Article

References (29)

1. Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB. Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma. Cancer 1979;43:1245-54.
2. Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987;107:25-30.
3. Cabanillas F, Bodey GP, Freireich EJ. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 1980;46: 2356-9.
4. Jones SE, Miller TP, Connors JM. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989;7:1186-91.
5. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6.
6. Tilly H, Mounier N, Lederlin P, et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. J Clin Oncol 2000;18:1309-15.
7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
8. The Non-Hodgkin's Lymphoma Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
9. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988;1:292-3. [Erratum, Lancet 1988;1:372.]
10. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988;1:292-3. [Erratum, Lancet 1988;1:372.]
11. Jaffe ES, Harris NL, Stein H, Vardiman J, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Vol. 3 of World Health Organization classification of tumours. Lyon, France: IARC Press, 2001.
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244. [Erratum, J Clin Oncol 2000;18:2351.]
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244. [Erratum, J Clin Oncol 2000;18:2351.]
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
16. Cox DR, Regression model and life-tables. J R Stat Soc [B] 1972;34:187-220.
17. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003;102:4284-9.
18. Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003;21:2466-73.
19. Pfreundschuh M, Truemper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33.
20. Miller TP, Leblanc M, Spier CM, Chase E, Fischer RI. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) Randomized Trial. Blood 2001;98: 742a-743a. abstract.
21. Savage K, Shipp MA. Initial evaluation: staging and prognostic factors. In: Mauch PM, Armitage J, Coiffier B, Dalla-Favera R, Harris N, eds. Non-Hodgkin's lymphomas. Philadelphia: Lippincott Williams & Wilkins, 2004:97-125.
22. Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 1999;94:3289-93.
23. Connors J. Principles of chemotherapy and combined modality therapy. In: Mauch PM, Armitage J, Coiffier B, Dalla-Favera R, Harris N, eds. Non-Hodgkin's lymphomas. Philadelphia: Lippincott Williams & Wilkins, 2004:201-19.
24. Dumontet C, Mounier N, Munck JN, et al. Factors predictive of early death in patients receiving high-dose CHOP (ACVBP regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Br J Haematol 2002;118:210-7.
25. Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197-204.
26. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906.
27. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348:2396-406.
28. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004;103:1222-8.
29. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.